Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of radiotherapy plus anlotinib for locoregional recurrent esophageal squamous cell carcinoma after radical surgery
ChiCTR1900025752Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Cancer Hospital. Primary endpoints: Objective response rate and Toxicity. Started Sep 2019; status: recruiting.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900025752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025752.